Aurelium

About Aurelium

About

Aurelium is an independent resource on ibogaine, ketamine, safety, evidence, and policy. It helps people understand complex developments without overstating benefits or minimizing risks.

Hands in a calm setting that reflects thoughtful treatment research

Why this exists

A steadier place to begin.

Questions around emerging treatment approaches can carry urgency, hope, uncertainty, and a great deal of conflicting information. Aurelium exists to make careful orientation easier: to identify what is known, where uncertainty remains, and which safety and policy questions deserve attention. Our independent treatment overview is designed as a starting point, not a substitute for individualized clinical or legal guidance.

Our editorial approach

Traceable, plainspoken, and alert to limits.

We organize information so readers can distinguish primary sources, research literature, official materials, and interpretation. Where a question turns on definitions or established terminology, we point readers toward durable references such as the clinical trial overview rather than treating isolated claims as settled fact.

We favor sources that can be checked, including registries, literature, and official guidance. For questions involving research records, readers can consult ClinicalTrials.gov’s study registry alongside the context we provide. The point is not to produce certainty where it does not exist; it is to make the basis for a statement easier to inspect.

Our coverage is arranged around the decisions and questions people actually encounter. That includes region-specific context, such as European treatment context, and topic-specific material like ibogaine HCl background, always with attention to the limits of general information.

Quiet landscape reflecting the careful pace of independent research

Editorial principles

How we hold the work.

These principles guide how Aurelium frames information, selects context, and signals uncertainty for patients, families, advocates, and policy-minded professionals.

  • 01

    Independent

    We are built to orient readers, not to promote a provider, program, or outcome.

  • 02

    Safety-aware

    Potential harm, contraindications, oversight, and uncertainty belong in the frame.

  • 03

    Evidence first

    We separate research signals from conclusions and note when evidence is limited.

  • 04

    Plain language

    Complex material should remain readable without losing the meaning of its limits.

Who this is for

For people seeking a clearer frame.

Aurelium is for people researching ibogaine and ketamine, including patients, families, advocates, and policy-minded professionals. Some readers arrive with questions shaped by a particular setting, including veteran-focused treatment questions or Texas-specific considerations. Others are comparing the language used across treatment and detox discussions.

Our guided topic pathways explain how the resource is organized, while the broader Aurelium reference provides a consistent entry point for related questions. We also surface focused context around detox center research, depression-related questions, and addiction treatment context without presenting any pathway as a recommendation.

Independent by design

Useful context, without a sales agenda.

Aurelium is an independent information resource. We do not operate as a clinic, medical provider, licensed treatment center, or legal authority. Nothing here is medical or legal advice, and no general resource can determine what is appropriate for a particular person.